LAURING, BRETT,ENGEL, SAMUEL S.,TERRA, STEVEN G.,RUSNAK, JAMES M.
申请号：
CA3016358
公开号：
CA3016358A1
申请日:
2017.03.06
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
